Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E31.64 EPS (ttm)1.00 Insider Own0.04% Shs Outstand6.08B Perf Week-3.44%
Market Cap192.84B Forward P/E12.06 EPS next Y2.63 Insider Trans-1.32% Shs Float6.06B Perf Month-3.47%
Income6.18B PEG4.67 EPS next Q0.50 Inst Own70.50% Short Float0.73% Perf Quarter-2.06%
Sales53.24B P/S3.62 EPS this Y-21.50% Inst Trans0.02% Short Ratio1.62 Perf Half Y-11.99%
Book/sh10.43 P/B3.04 EPS next Y8.77% ROA3.60% Target Price37.65 Perf Year7.30%
Cash/sh2.36 P/C13.42 EPS next 5Y6.77% ROE9.70% 52W Range27.49 - 36.72 Perf YTD-2.40%
Dividend1.28 P/FCF108.28 EPS past 5Y1.60% ROI7.30% 52W High-13.66% Beta0.94
Dividend %4.04% Quick Ratio0.90 Sales past 5Y-5.60% Gross Margin76.60% 52W Low15.30% ATR0.50
Employees97900 Current Ratio1.10 Sales Q/Q7.90% Oper. Margin15.10% RSI (14)36.03 Volatility1.42% 1.26%
OptionableYes Debt/Eq0.70 EPS Q/Q-36.80% Profit Margin11.60% Rel Volume0.95 Prev Close32.03
ShortableYes LT Debt/Eq0.48 EarningsJan 31 BMO Payout116.50% Avg Volume27.46M Price31.70
Recom2.50 SMA20-3.22% SMA50-1.44% SMA200-4.73% Volume26,093,306 Change-1.03%
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Jan-19-17 04:06PM  What Lies Ahead for Pharma ETFs?
04:01PM  Exxon Mobil, Merck Weigh on DJIA Thursday
12:56PM  Top Analyst Reports for Gilead Sciences, Las Vegas Sands & Illinois Tool Works
11:58AM  Pfizer Continues to Tank -- Get Ready to Buy on the Dip
08:00AM  Milner Therapeutics Institute Announces New Partnership with US Pharmaceutical Company Pfizer PR Newswire
07:30AM  [$$] Gormley's Take: In Role Reversal, Pharmaceutical Giants Turn to Biotech Startups for Help at The Wall Street Journal
Jan-18-17 06:31PM  How to improve your sex life without breaking the bank
04:41PM  5 Expensive Drugs That Could End Up in Trump's Crosshairs at Motley Fool
12:12PM  Trump health pick Price defends investments, Obamacare replacement Reuters
10:45AM  There May Be a Buying Opportunity When Pfizer Shares Hit This Important Level at TheStreet
09:54AM  Pfizer Inc. breached its 50 day moving average in a Bearish Manner : PFE-US : January 18, 2017
07:25AM  Allergan Rebounding With Strong Product Pipeline, Smart Acquisitions
06:00AM  Trump's health pick set to defend investments at U.S. Senate hearing Reuters
05:40AM  [$$] Pfizer warns of 'big challenge' ahead from strong dollar at Financial Times
Jan-17-17 06:02PM  Pfizer CEO: This is what Trump doesnt understand about the pharma industry at CNBC
05:33PM  AARP CEO: Trumpcare needs these 4 basic principles
04:01PM  JPMorgan, Goldman Sachs Sink DJIA on Tuesday
12:27PM  Should Pfizer, Inc. Be on Your Stock Watchlist? at Motley Fool
09:59AM  Why Bristol-Myers Squibb May Be a Merger Target Soon
09:45AM  Double Down On Dividends With These 2 Covered Calls at Insider Monkey
08:40AM  4 Dow Stocks Every Retiree Should Own at Kiplinger
08:11AM  One Simple Step to Building a Smarter Portfolio at Motley Fool
07:30AM  [$$] OncoImmune Picks Up $15 Million for Immune-Based Disease Treatments at The Wall Street Journal
Jan-16-17 10:14AM  These 5 Drug Patents Will Expire in 2017 at Investopedia
08:38AM  5 Trump-Proof Pharma Dividends Up To 5.3% at Forbes
07:39AM  Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended
07:37AM  How Does Novartiss Valuation Compare to Peers?
07:27AM  Is Donald Trump Big Pharma's Worst Nightmare? at Motley Fool
Jan-15-17 10:20AM  [$$] Ireland: Brexit vote forces Dublin to seek new EU friends at Financial Times
Jan-13-17 04:20PM  10 Best Dividend-Paying Stocks for 2017 at Kiplinger
03:44PM  Options Insight: How to Play Pfizer
03:24PM  It's Full Speed Ahead for Opko Health After Pipeline Stumble at Motley Fool
11:00AM  Versartis' Pipeline Holds Big Promise
08:40AM  5 Stocks With Bigger Dividends Than ExxonMobil at Motley Fool
Jan-12-17 05:10PM  Trumps HHS nominee has promised to divest from these Mass. companies at bizjournals.com
04:25PM  3 Surprises From Pfizer at the J. P. Morgan Healthcare Conference at Motley Fool
04:01PM  Disney, Microsoft Lead DJIA Drop Thursday
03:22PM  Investors in big pharma, biotech look to ride out Trump storm
08:43AM  Merck KGaA, Vertex Announce Tie-Up for Oncology Programs
07:37AM  Understanding Mylans Revenues
01:43AM  Trump Attacks Drugmakers on Pricing at The Wall Street Journal
Jan-11-17 04:19PM  Trump Says Drugmakers 'Getting Away With Murder', Cites F-35, Ford, Fiat
04:16PM  Trump Attacks Drugmakers on Pricing at The Wall Street Journal
04:10PM  Markets Right Now: Stocks end a wobbly day with solid gains
03:58PM  Pisani: Market's a tightly-coiled spring right now
03:22PM  Wednesdays Top Biopharma Movers
01:41PM  Trump Shoots Down Biotechs, Lockheed; Apple, Nvidia Weigh On Nasdaq
Jan-10-17 07:07PM  US warns of unusual cybersecurity flaw in heart devices
06:15PM  Celebrate One Debacle of a Merger With Another -- ICYMI
04:38PM  10 Biggest Problems In The World That Can Be Solved With Inventions at Insider Monkey
03:41PM  How a Bust Caused Opko Health Shares to Tumble in 2016 at Motley Fool
01:40PM  1 Perfect Stock to Invest in the Pharmaceutical Industry at Motley Fool
12:59PM  Todd Hagopian's Top Biotech Takeover Targets For 2017 at Forbes
11:36AM  Best Dividend Stocks For Retirement Income In 2017 at Forbes
11:32AM  Pfizer Inc. : PFE-US: Dividend Analysis : November 11th, 2016 (record date) : By the numbers : January 10, 2017
11:01AM  Forester Value Fund Quarterly Update
10:42AM  Pfizer Inc. (PFE) Challenges Businessmen To Come Up With Breast Cancer Solutions at Insider Monkey
08:24AM  3 'Dogs of the Dow' Paying Up To 4.3% at Forbes
Jan-09-17 06:51PM  Cramer names the 'humanization of pets' as the greatest investing theme in the market at CNBC
02:19PM  Piper Bullish On Pfizer and Eli Lilly at Investopedia
12:24PM  2 Reasons Pfizer's Stock Beat the Field in 2016 at Motley Fool
08:51AM  This Stock Prevented The Dow From Hitting Key Milestone at Forbes
06:09AM  Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)
Jan-08-17 02:18PM  5 Trade Ideas for Monday: AIG, CME, Honeywell, McDonald's and Pfizer
Jan-07-17 11:13AM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer at Motley Fool
Jan-06-17 11:37AM  ICU Medical Wins Big Price Cut to Buy Pfizer's Hospira Unit
08:48AM  [$$] Carlyle looks to sell health business Nature's Bounty at Financial Times
08:21AM  Pfizer's Humira Biosimilar Meets Primary Endpoint in Study
07:24AM  Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View
Jan-05-17 05:26PM  Pfizer Unveils Positive Results from Study of Potential Humira Biosimilar
04:39PM  Spark Gets A Check From Pfizer And A Downgrade From Vetr
04:05PM  ICU Medical, Inc. Provides Update on Hospira Infusion Systems Transaction GlobeNewswire
12:36PM  Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio
11:05AM  2017 Bull-Bear Case for Health Care: J&J, Merck, Pfizer, UnitedHealth
10:09AM  Spark Therapeutics Gets $15M Milestone Payment from Pfizer
09:43AM  The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016 at Motley Fool
09:41AM  What Pharma and Health Care Investors Should Watch for at JPM
09:30AM  The Zacks Analyst Blog Highlights: Verizon Communications, Pfizer, Chevron, Caterpillar and ExxonMobil
09:02AM  AbCellera Announces Multi-Target Research Collaboration with Pfizer GlobeNewswire
09:00AM  AbCellera Announces Multi-Target Research Collaboration with Pfizer GlobeNewswire
08:30AM  Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab) Business Wire
06:02AM  Here's When to Buy Chevron, IBM, 3 More High-Yielding Dow 'Dogs'
06:00AM  Molecular Stethoscope Completes $8.2M Seed Financing to Advance Circulating Cell-Free RNA Liquid Biopsy Platform; Announces Research Collaboration with Pfizer PR Newswire
06:00AM  For People With Disabilities, ABLE Accounts a Step Toward Independence at Morningstar
Jan-04-17 06:17PM  Why Encana, Acadia Pharmaceuticals, and Tenet Healthcare Jumped Today at Motley Fool
04:43PM  Here's Why Acadia Pharmaceuticals Inc. Stock Is Up Today at Motley Fool
03:56PM  What's Next for Opko Health After Its Recent Clinical Setback? at Motley Fool
03:30PM  3 Reasons to Buy Pfizer Stock for Retirement at Kiplinger
01:40PM  Spark reels in second $15M payment from Pfizer at bizjournals.com
09:30AM  The Zacks Analyst Blog Highlights: UnitedHealth, Pfizer, Lockheed Martin, 3M and TripAdvisor
09:30AM  Pfizer Is Cheap, but Is Still a Dog Stock
09:12AM  5 Dogs of the Dow Stocks for 2017
07:30AM  Spark Therapeutics Announces $15 Million Milestone Payment from Pfizer for Progress in Hemophilia B Gene Therapy Program GlobeNewswire
06:54AM  The price of a lifesaving drug that reverses opioid overdoses is soaring at CNBC
06:25AM  4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017
Jan-03-17 06:00PM  From Bamboo Therapeutics to Undercover Colors: Top Triangle fundraises in 2016 at bizjournals.com
02:09PM  2017 stock picker's playbook
12:48PM  Stock Research Reports for Pfizer, Lockheed Martin & UnitedHealth
11:00AM  Pfizer Invites Public To View And Listen To Webcast Of January 31 Conference Call With Analysts Business Wire
10:00AM  Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, and Transgene S.A.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh; and a strategic collaboration agreement with IGNITE Immunotherapy Inc. It also has a collaboration with AbCellera Biologics Inc. to discover therapeutic antibodies against undisclosed membrane protein targets. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 07Option Exercise25.8730,000776,100167,687Dec 08 09:48 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 09Sale33.0010,000330,000112,087Nov 10 07:44 PM
BOURLA ALBERTGroup PresidentNov 04Option Exercise24.9920,000499,800149,199Nov 07 05:58 PM
BOURLA ALBERTGroup PresidentNov 04Sale30.0518,390552,530130,809Nov 07 05:58 PM
HILL CHARLES HExecutive Vice PresidentNov 03Option Exercise21.0353,9181,133,896115,033Nov 07 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 02Option Exercise21.0332,545684,421122,087Nov 04 04:36 PM
DAMELIO FRANK AExecutive Vice PresidentMay 26Option Exercise24.43100,0002,443,000472,994May 27 11:03 AM
DAMELIO FRANK AExecutive Vice PresidentMay 26Sale34.49100,0003,449,115372,994May 27 11:03 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Option Exercise25.8786,0002,224,820271,663May 26 10:07 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Sale33.9786,0002,921,147185,663May 26 10:07 AM
YOUNG JOHN DGroup PresidentMay 10Option Exercise25.8741,7001,078,779200,399May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Option Exercise24.43192,0004,690,560564,994May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Sale33.66192,0006,462,579372,994May 11 06:04 PM
YOUNG JOHN DGroup PresidentMay 10Sale33.5341,7001,398,277158,699May 11 06:04 PM
READ IAN CChairman & CEOMay 09Option Exercise25.74275,0007,078,2501,471,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Option Exercise22.2823,884532,136199,735May 11 04:35 PM
HILL CHARLES HExecutive Vice PresidentMay 09Sale33.8429,6001,001,65160,828May 11 04:35 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Sale33.7167,8842,288,669131,851May 11 04:35 PM
READ IAN CChairman & CEOMay 09Sale33.80275,0009,295,0391,196,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 05Option Exercise22.2856,0161,248,036231,867May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 05Sale33.7156,0161,888,144175,851May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Option Exercise22.2820,100447,828195,951May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Sale33.8720,100680,762175,851May 06 09:51 AM
DAMELIO FRANK AExecutive Vice PresidentMay 03Sale33.6587,0792,930,208372,994May 05 05:27 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541274,756Feb 26 03:05 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 24Option Exercise18.9062,4531,180,362140,772Feb 26 03:05 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9018,984358,79889,467Feb 26 03:05 PM
READ IAN CChairman & CEOFeb 24Option Exercise18.90584,11211,039,7172,030,151Feb 26 03:05 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541263,151Feb 26 03:05 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9052,570993,573188,679Feb 26 03:05 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9034,171645,832210,943Feb 26 03:05 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90210,2803,974,292622,467Feb 26 03:05 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90210,2803,974,292577,902Feb 26 03:05 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9078,8551,490,360149,135Feb 26 03:05 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9019,188362,65366,048Feb 26 03:05 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9034,171645,832149,482Feb 26 03:05 PM
BOURLA ALBERTGroup PresidentFeb 24Option Exercise18.9030,666579,587144,675Feb 26 03:03 PM